Clinical trials: Weightloss
Obesity, Type 2 Diabetes
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.
- Trial name
- NCT02324491
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 16 sites in Australia
- Volunteers
- 152 people
- Sponsor
- Zafgen, Inc.
Muscle Wasting, Obesity & Overweight
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more…
- Conditions
- Muscle Wasting, Obesity & Overweight, Obesity
- Trial name
- OBA (NCT07411378)
- Testing
- BIO101, Semaglutide
- Volunteers
- 164 people
- Sponsor
- Biophytis
Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial.
- Conditions
- Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure, Overweight (BMI > 25)
- Trial name
- LiveWell (NCT07560579)
- Testing
- Educational curriculum, Weight loss Application, Urinary EDC metabolite testing
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Million Marker Wellness, Inc.
Type 2 Diabetes Mellitus, Weight Loss
A Clinical Study of Mass Balance of [14C]HRS-7535
The objective is to evaluate the mass balance of [14C]HRS-7535 in healthy adult Chinese subjects.
- Trial name
- NCT06819488
- Testing
- [14C]HRS-7535
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Weight Loss
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT01905956
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research…
- Trial name
- COSMOS-DIGITAL (NCT06761703)
- Testing
- TAP® Micro Select Device (Touch Activated Phlebotomy)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amgen
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Obesity
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity.
- Trial name
- NCT04707313
- Testing
- PF-06882961 (Cohorts 1 and 2), PF-06882961 (Cohort 3)
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 628 people
- Sponsor
- Pfizer
Randomized Versus Placebo, Controlled
Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo
Clinical intervention on overweight or moderately obeses adults. The objective of this trial is to demonstrate the superior eficacy of Alphagos to placebo on weight loss during a low-calorie diet of 12 weeks.
- Conditions
- Randomized Versus Placebo, Controlled, Double Blind
- Trial name
- NCT02228746
- Testing
- Alpha-galacto-oligosaccharides
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Olygose
Overweight, Obesity
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
Study design to demonstrate the safety and performance of the Epitomee Device
- Trial name
- NCT03610958
- Testing
- Epitomee Device
- Where
- Israel
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Epitomee medical